Press Releases

Second China CyberKnife® Forum Provides Platform to Share Knowledge and Experience on Accuray’s CyberKnife System

SUNNYVALE, Calif., December 21, 2012 – Accuray Incorporated (Nasdaq: ARAY) announced today that about 100 attendees from hospitals using CyberKnife® Systems in China were brought together at the Second China CyberKnife Forum, co-organized by the Radiation Oncology Committees of Chinese Anti-Cancer Association and Chinese Medical Association, which was held at Huashan Hospital, Shanghai on November 23-24, 2012.

 “The China CyberKnife Forum provides a great platform to discuss the clinical applications and share best practices among users in the country, which we hope will ultimately bring greater benefits to patients,” said Prof. Pan, director of the CyberKnife and Gamma-knife Center, “In its second year, the Forum featured more in-depth discussions for an expanding range of clinical indications and now plays a very vital role not only for new users but existing users to share knowledge and experience.”

This year's Forum featured clinical and technical presentations on a broad range of CyberKnife indications including intracranial, lung, liver, prostate and pancreatic tumors. Regional and international speakers invited by Accuray also shared best practices on the use and efficacy of the CyberKnife System in treating prostate and lung tumors in Taiwan and the United States respectively.

“The CyberKnife Forum continues to be invaluable in learning and sharing among our clinicians. The clinical data presented during this year’s forum supports the growing usage of full-body radiosurgery in China. It also highlights CyberKnife clinical excellence in providing safe, effective and comfortable care for patients,” said Cynthia Chan, M.D., senior director of medical affairs, Accuray Asia.

During the Forum, valid treatment guidelines for different pathologies, the importance of combining different and sequential treatment modalities and various treatment challenges were shared.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 667 systems have been installed in leading hospitals around the world. For more information, please visit

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, and the Company’s leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors” in the company’s report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Q filed on November 8, 2012 and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.  Accordingly, investors should not place undue reliance on any forward-looking statements.